logo
logo
Molina Healthcare, Inc.

Molina Healthcare, Inc.

NYSE•MOH
CEO: Mr. Joseph Michael Zubretsky
セクター: Healthcare
業種: Medical - Healthcare Plans
上場日: 2003-07-02
Molina Healthcare, Inc. provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments: Medicaid, Medicare, Marketplace, and Other. The company served in across 19 states. The company was founded in 1980 and is headquartered in Long Beach, California.
連絡先情報
200 Oceangate, Suite 100, Long Beach, CA, 90802, United States
562-435-3666
www.molinahealthcare.com
時価総額
$6.96B
PER (TTM)
14.6
47
配当利回り
--
52週高値
$359.97
52週安値
$121.06
52週レンジ
6%
順位28Top 16.1%
5.3
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$11.38B+0.00%
直近4四半期の推移

EPS

-$3.15+0.00%
直近4四半期の推移

フリーCF

-$297.00M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Premium Revenue Increased 11% Premium revenue reached $43.1B USD, up 11% driven by ConnectiCare acquisition and Medicaid rate increases.
Net Income Dropped Significantly Net income fell to $472M USD from $1.179B USD due to higher medical costs outpacing revenue rates.
Medical Care Ratio Spiked Consolidated MCR rose 260 basis points to 91.7% reflecting challenging medical cost trends across all operating segments.
Medicaid Membership Declined Total membership slightly decreased to 5.491M members; Medicaid lost 322K members due to eligibility redeterminations.

リスク要因

Medicaid Rates Lag Costs Fixed Medicaid rates may not keep pace with rising utilization and medical cost trends, compressing margins significantly.
Marketplace Subsidy Expiration Expiration of enhanced premium tax credits (APTCs) after 2025 could reduce Marketplace participation and membership levels.
OBBBA Medicaid Enrollment Risk New OBBBA legislation expected to cause 15% to 20% reduction in Medicaid Expansion enrollment by 2029.
Incurred Claims Estimation Risk Estimating IBNP liability requires significant judgment; cost trend variations could materially impact financial results.

見通し

Pursuing Government Contracts Strategy focuses on pure-play government business, targeting 11% to 13% long-term premium revenue growth.
Exiting MAPD Product Line Intends to exit MAPD product in 2027 to focus exclusively on higher acuity dual-eligible Medicare members.
Share Repurchase Authorization Board authorized up to $1B share repurchase program through December 31, 2026, demonstrating capital deployment focus.
New Contract Revenue Secured 2025 RFP wins secured nearly $9B in incremental annual Medicaid premium revenue expected to commence in 2026.

同業比較

売上高 (TTM)

Molina Healthcare, Inc.MOH
$45.43B
+11.7%
DaVita Inc.DVA
$13.64B
+6.5%
Henry Schein, Inc.HSIC
$12.94B
+3.5%

粗利益率 (最新四半期)

Halozyme Therapeutics, Inc.HALO
84.4%
+1.4pp
BioMarin Pharmaceutical Inc.BMRN
81.2%
+7.2pp
Penumbra, Inc.PEN
67.8%
+1.2pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
MRNA$16.50B-5.9-30.1%10.2%
ALGN$13.40B32.610.4%1.3%
PEN$13.31B80.813.1%12.4%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
0.7%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
25%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年4月21日
|
EPS:-
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-K - FY 2025

    会計期末: 2025年12月31日|提出日: 2026年2月10日|
    売上高: $45.43B+11.7%
    |
    EPS: $8.93-56.5%
    予想を上回る

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年10月23日|
    売上高: $11.48B+11.0%
    |
    EPS: $1.51-73.3%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年7月24日|
    売上高: $11.43B+15.7%
    |
    EPS: $4.76-8.5%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年4月24日|
    売上高: $11.15B+12.2%
    |
    EPS: $5.47+5.2%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月11日|
    売上高: $40.65B+19.3%
    |
    EPS: $20.52+9.7%
    予想を上回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年10月24日|
    売上高: $10.34B+21.0%
    |
    EPS: $5.66+33.5%
    予想通り

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年7月25日|
    売上高: $9.88B+18.6%
    |
    EPS: $5.20-3.0%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年4月25日|
    売上高: $9.93B+21.9%
    |
    EPS: $5.20-6.0%
    予想を下回る